Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that the Company will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024.
2024年8月27日(環球新聞)- Medicenna Therapeutics Corp.(以下簡稱「Medicenna」或「公司」)(TSX: MDNA,OTCQB: MDNAF)是一家臨床階段免疫療法公司,專注於超級肽鏈的開發,今天宣佈該公司將在巴黎國際會議中心的Promise of Interleukin-2 Therapy Conference上發表兩個摘要,都是口頭報告,會議將於2024年9月4-7日在法國巴黎蘇爾邦大學國際會議中心舉行。
The Company will present preclinical data for the first time on its MDNA209 platform, featuring long-acting, high-affinity IL-2β biased IL-2/IL-15 Super-antagonists with therapeutic potential for autoimmune and graft-versus-host diseases. Additionally, further preclinical data will be presented on MDNA113, the Company's novel first-in-class IL-13Rα2 tumor-targeted and tumor-activated bifunctional anti-PD1-IL-2 Superkine.
公司將首次提供其MDNA209平台的臨床前數據,該平台具有長效、高親和力的IL-2β偏愛IL-2/IL-15超拮抗劑,具有治療自身免疫性疾病和移植物抗宿主疾病的潛力。此外,還將展示MDNA113的臨床前數據,該公司的新型一類IL-13Rα2腫瘤靶向和腫瘤活化雙重功能抗PD1-IL-2超肽。
Details for the oral presentations are as follows:
口頭報告的詳細信息如下:
Title: MDNA209, a High Affinity IL-2β Biased IL-2/IL-15 Super-antagonist, for the Treatment of Autoimmune Diseases
Presenter: Dr. Hardeep Kataria
Session Title: Novel IL-2s, Vectorization and Combination Therapies
Session Date and Time: Friday September 6, 2024; 2 PM CEST (8 AM EST)
標題: MDNA209, 一種高親和力IL-2β偏愛IL-2/IL-15超拮抗劑,用於治療自身免疫性疾病
演講者: Dr. Hardeep Kataria
會議主題: 新型IL-2,載體化和聯合療法
會議日期和時間: 2024年9月6日星期五; 上午8點(東部標準時間)
Title: MDNA113, an IL-13Rα2 Tumor Targeting and Conditionally Activatable anti-PD1-IL-2SK BiSKIT Shows Enhanced Safety and Potent Therapeutic Efficacy
Presenter: Dr. Minh To
Session Title: IL-2 in Cancer Therapy
Session Date and Time: Saturday September 7, 2024; 9 AM CEST (3 AM EST)
標題: MDNA113,一種針對IL-13Rα2腫瘤的封閉式激活型抗PD1-IL-2Sk BiSK,顯示出增強的安全性和強效的治療效果
演講者: 阮明博士
會議主題: 癌症治療中的IL-2
會議日期和時間: 2024年9月7日星期六; 上午3點(東部標準時間)
Following the conclusion of the Promise of Interleukin-2 Therapy Conference, copies of the presentations will be available on the "Scientific Presentations" page of Medicenna's website.
在白細胞介素-2療法承諾會議結束後,演講的副本將在Medicenna網站的「科學演講」頁面上提供。
About Medicenna Therapeutics
關於醫藥技術公司Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna's early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically "cold" tumors.
Medicenna是一家臨床階段的免疫治療公司,專注於開發IL-2、IL-4和IL-13超強素的新型、高選擇性版本以及獨家超強素。Medicenna的長效IL-2超強素MDNA11是下一代IL-2,具有對CD122(IL-2受體β)具有優越的親和力,且不結合CD25(IL-2受體α),因此優先刺激癌殺傷效應T細胞和NK細胞。Medicenna的IL-4增強超強素bizaxofusp(前MDNA55)已在5項臨床試驗中研究,招募了130多名患者,包括一項針對複發性GBm的20億期試驗,這是最常見且統一致命的腦癌形式。Bizaxofusp已獲得FDA的FastTrack和FDA / EMA的孤兒藥物地位。Medicenna的早期高親和力IL-2β偏好IL-2/IL-15超-拮抗素來自其MDNA209平台,正在評估其作爲自身免疫和移植物抗宿主病的潛在療法。Medicenna的早期BiSKITs(雙功能超強素免疫療法)和t-MASk(靶向金屬蛋白酶活化超強素)項目旨在增強超強素治療免疫「冷」腫瘤的能力。
For more information, please visit , and follow us on Twitter and LinkedIn.
有關更多信息,請訪問 ,並在我們之後的推特上關注我們。推特和頁面。LinkedIn.
Forward-Looking Statements
前瞻性聲明
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts, such as statements on the therapeutic potential and safety profile of MDNA209 and MDNA113. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
本新聞稿包含根據適用證券法的前瞻性陳述。前瞻性陳述包括但不限於有關公司未來業務運營、估計、計劃、戰略雄心、合作伙伴活動與機會、目標、期望、意見、預測、投影、指導、展望或其他陳述,旨在說明MDNA209和MDNA113的治療潛力和安全性等的表述,並非歷史事實。藥物研發和商業化面臨很高的風險,只有少數研發項目能夠商業化。早期臨床前或臨床研究的結果可能不代表全部結果,也不能確保來自後期或更大規模臨床研究的結果或獲得監管批准。您不應過度依賴這些陳述或科學數據的呈現。
Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expect", "believe", "seek", "potentially" and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
前瞻性聲明通常可根據"將"、"可能"、"應"、"預計"、"預期"、"相信"、"尋求"、"潛在"等表達方式進行識別,並受風險和不確定性的影響。不能保證此類聲明會被證明準確,實際結果和未來事件可能與該類聲明中預期的有重大差異。可能導致實際結果與公司預期有重大差異的重要因素包括公司最新年度信息表格中詳細列出的風險,以及公司不時向加拿大適用證券監管機構提交的其他備案文件中的風險。
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
讀者應當注意,在準備任何前瞻性信息時所做的假設有可能被證明是不正確的。由於無數已知和未知的風險、不確定性和其他因素,大量已知和未知的風險、不確定性和其他因素可能導致事件或情況導致實際結果與預測結果不同,這是由於公司無法控制。讀者被警告不要過度依賴任何前瞻性信息。儘管管理層認爲這些信息是合理的,但這些信息有可能被證明是不正確的,實際結果可能與預期的結果有很大不同。本新聞發佈所包含的前瞻性聲明在此謹此聲明。本新聞發佈所包含的前瞻性聲明是根據此處的日期進行的,除非法律要求,否則我們沒有意圖並不會承擔更新或修訂所包含的前瞻性聲明的任何義務。
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
本新聞稿含有超鏈接到未被視爲本新聞稿參考的信息。
Investor/Media Contact:
投資者/媒體聯繫方式:
Christina Cameron
Investor Relations, Medicenna Therapeutics
(647) 953-0673
ir@medicenna.com
Christina Cameron
投資者關係,Medicenna Therapeutics
(647) 953-0673
ir@medicenna.com